Risk Factors and Management of Hepatitis B Virus Reactivation in Patients With Hematological Disorders

Basit Öğe Kaydı
dc.contributor.authorAkay, Fatih Erkan
dc.contributor.authorTan, Berfin
dc.contributor.authorGüldağ, Mahmut Alper
dc.contributor.authorÇifcibaşı, Hilal Sena
dc.contributor.authorElmacı, Kubilay
dc.contributor.authorÜmit, Elif Gülsüm
dc.date.accessioned2021-11-20T10:27:10Z
dc.date.available2021-11-20T10:27:10Z
dc.date.issued2018
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.description.abstractAims: The aim of this study is to evaluate hepatitis B virus serological status and to categorize the risks of our treatmentmodalities in patients with both benign and malignant hematological disorders.Methods: This was a retrospective study of 552 patients who were admitted to the Trakya University Hospital Hematologyunit between 01.01.2017 and 31.12.2017. All data regarding the diagnosis, treatment and HBV serologicalstatus were collected from patient files. Data were analyzed with IBM SPSS V.20 using descriptive statistical analysis.Results: Hepatitis B surface antigen was positive in 45 (8.2%) patients, antibody to the hepatitis B surface antigenwas positive in 279 (50.5%) patients and antibody to the hepatitis B core antigen was positive in 247 (44.7%) patients.According to these results, 32 patients were found to be vaccinated for hepatitis B virus. Reactivation was observed in4 (0.7%) patients who have been hepatitis B surface antigen positive and have received adequate duration of antiviralprophylaxis with tenofovir. These 4 patients have received monoclonal antibody for immunosuppressive treatment.Conclusion: To conclude, although the rate of hepatitis B surface antigen reactivation is quite low, as many patientsas possible should be vaccinated to reduce the costs of antiviral treatments and monitorization. If there is notime to vaccinate, patients should be categorized according to guidelines by their hepatitis B surface antigen serologicalstatus and by the planned immunosuppressive treatments.en_US
dc.identifier.dergipark420829en_US
dc.identifier.endpage4en_US
dc.identifier.issn2148-4724
dc.identifier.issn2548-0030
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://dergipark.org.tr/tr/pub/tmsj/issue/36656/420829
dc.identifier.urihttps://dergipark.org.tr/tr/download/article-file/467615
dc.identifier.urihttps://hdl.handle.net/20.500.14551/6293
dc.identifier.volume5en_US
dc.language.isoenen_US
dc.publisherTrakya Üniversitesien_US
dc.relation.ispartofTurkish Medical Student Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitisen_US
dc.subjecthematologyen_US
dc.subjectimmunotherapyen_US
dc.titleRisk Factors and Management of Hepatitis B Virus Reactivation in Patients With Hematological Disordersen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
6293.pdf
Boyut:
680.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Turkish Medical Student Journal
Makale Koleksiyonu